【摘要】 目的研究和评价罗红霉素辅助治疗复治肺结核疗效。方法将138例复治肺结核患者随机分为:治疗组70例,采用3PaZ(TH)L2VAKE+罗红霉素/3PaZ(TH)L2VE/9PaL2E方案化疗(Pa:力克肺疾,Z:吡嗪酰胺,TH:丙硫异烟胺,L:利福喷丁,V:左氧氟沙星,E:乙胺丁醇,AK:阿米卡星);对照组68例,采用3PaZ(TH)L2VAKE/3PaZ(TH)L2VE/9PaL2E方案化疗。结果完成疗程可评价疗效者133例,其中治疗组67例,对照组66例。治疗第1、3个月痰菌阴转率治疗组分别为33.3%和66.7%,对照组分别为10.7%和39.3%,差异有显著性(P<0.05)。治疗3个月时,治疗组和对照组显效率分别为34.3%和9.0%,治疗结束时治疗组和对照组显效率分别为62.9%和42.4%,差异有显著性(P<0.05)。无严重不良反应。结论罗红霉素辅助治疗复治肺结核,是一种安全、可靠的抗生素。更多还原

【Abstract】 Objective To study and evaluate the efficacy of roxithromycin In the treatment of pulmonary tuberculosis.Methods One hundred thirty-eight cases with re-treated pulmonary tuberculosis were randomly divided into a trial group [70 cases,treated with 3PaZ(TH)L2VAKE+roxithromycin/3PaZ(TH)L2VE/9PaL2E] and a control group [68 cases,treated with 3PaZ(TH)L2VAKE/3PaZ(TH)L2VE/9PaL2E] The efficacy of 133 cases was available for evaluation when the course was completed(the trial group of 67 cases and the control group of 66 cases).Results The sputum smear-negative conversion rates at the 1st and the 3rd month of the therapy were 33.3% and 66.7% in the trial group,and 10.7% and 39.3% in the control group(P<0.05).At the 3rd month of the therapy,the X-ray salience resolution rates were 34.3% and 9.0%,respectively,in the trial and the control groups(P<0.01).At the completion of the therapy,the X-ray salience resolution rates were 62.9% and 42.2%,respectively,in the trial group and in the control groups(P<0.01).Roxithromycin associated side effects were rare.Conclusion As an effective and safe antibiotic,roxithromycin can be added to the standard chemotherapy for pulomonary tuberculosis.更多还原